Dr. Zauderer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
19 Bradhurst Ave
Ste 2100N
Hawthorne, NY 10532Phone+1 914-493-8375Fax+1 914-347-1832
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
Columbia University Vagelos College of Physicians and SurgeonsClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2007 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Clinical and Histopathologic Characteristics of BAP1 Mutations Start of enrollment: 2013 Jan 01
- Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Start of enrollment: 2015 May 01
- Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Start of enrollment: 2017 Oct 05
- Join now to see all
Publications & Presentations
PubMed
- 273 citationsMesothelioma: Scientific clues for prevention, diagnosis, and therapy.Michele Carbone, Prasad S. Adusumilli, H. Richard Alexander, Paul Baas, Fabrizio Bardelli
CA. 2019-09-01 - 9 citationsWorkshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry.Kristin J. Cummings, Michael J. Becich, David J. Blackley, Dennis Deapen, Robert Harrison
American Journal of Industrial Medicine. 2020-02-01 - 158 citationsCOVID-19 in patients with lung cancerJia Luo, Hira Rizvi, Isabel Ruth Preeshagul, Jacklynn V. Egger, David Hoyos
Annals of Oncology. 2020-10-01
Lectures
- Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.2019 ASCO Annual Meeting - 6/1/2019
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactiva...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
MSK Research Highlights, November 23, 2022November 23rd, 2022- MARF to Host International Symposium on Malignant MesotheliomaJuly 20th, 2022
- ‘Promising’ Durvalumab Results Spark Phase 3 Trial in MesotheliomaJune 4th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
